T
T. Jake Liang
Researcher at National Institutes of Health
Publications - 241
Citations - 25949
T. Jake Liang is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Hepatitis C virus & Hepatitis C. The author has an hindex of 85, co-authored 233 publications receiving 24158 citations. Previous affiliations of T. Jake Liang include Harvard University & United States Department of Health and Human Services.
Papers
More filters
Journal ArticleDOI
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome
Takaji Wakita,Thomas Pietschmann,Takanobu Kato,Takanobu Kato,Tomoko Date,Michiko Miyamoto,Zijiang Zhao,Krishna K. Murthy,Anja Habermann,Hans-Georg Kräusslich,Masashi Mizokami,Ralf Bartenschlager,T. Jake Liang +12 more
TL;DR: It is shown that the JFH1 genome replicates efficiently and supports secretion of viral particles after transfection into a human hepatoma cell line (Huh7) and provides a powerful tool for studying the viral life cycle and developing antiviral strategies.
Journal ArticleDOI
Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.
Julie Lucifora,Yuchen Xia,Florian Reisinger,Ke Zhang,Daniela Stadler,Xiaoming Cheng,Martin F. Sprinzl,Herwig Koppensteiner,Zuzanna Makowska,Tassilo Volz,Caroline Remouchamps,Wen Min Chou,Wolfgang E. Thasler,Norbert Hüser,David Durantel,T. Jake Liang,Carsten Münk,Markus H. Heim,Jeffrey L. Browning,Emmanuel Dejardin,Maura Dandri,Michael Schindler,Mathias Heikenwalder,Ulrike Protzer +23 more
TL;DR: It is described how interferon-α can induce specific degradation of the nuclear viral DNA without hepatotoxicity and proposed lymphotoxin-β receptor activation as a therapeutic alternative and the development of new therapeutics that, in combination with existing antivirals, may cure hepatitis B.
Journal ArticleDOI
Hepatitis B: the virus and disease.
TL;DR: Virological and serological assays have been developed for diagnosis of various forms of HBV‐associated disease and for treatment of chronic hepatitis B infection and an unmet need to understand the molecular, cellular, immunological, and genetic basis of various disease manifestations associated with HBV infection is understood.
Journal ArticleDOI
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.
Kittichai Promrat,Glen Lutchman,Gabriel I. Uwaifo,Renee J. Freedman,Alejandro Soza,Theo Heller,Edward Doo,Marc G. Ghany,Ahalya Premkumar,Yoon Park,T. Jake Liang,Jack A. Yanovski,David E. Kleiner,Jay H. Hoofnagle +13 more
TL;DR: It is indicated that treatment with an insulin‐sensitizing agent can lead to improvement in biochemical and histological features of NASH and support the role of insulin resistance in the pathogenesis of this disease.
Journal ArticleDOI
Impaired Effector Function of Hepatitis C Virus-Specific CD8+ T Cells in Chronic Hepatitis C Virus Infection
Heiner Wedemeyer,Xiao-Song He,Michelina Nascimbeni,Anthony R. Davis,Harry B. Greenberg,Jay H. Hoofnagle,T. Jake Liang,Harvey J. Alter,Barbara Rehermann +8 more
TL;DR: The defective functions of HCV-specific CD8+ T cells might contribute to viral persistence in chronically infected patients, and knowledge on their reversibility may facilitate the development of immunotherapeutic vaccines.